Pharming Group's Upcoming Investor Conference Engagement
Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) is excited to announce its participation in an important investor conference taking place this March. With a focus on connecting with investors and stakeholders, Pharming’s management will engage at this event to highlight their ongoing contributions to the biopharmaceutical landscape.
About the Conference
The key focus of this event is the 37th Annual Roth Conference, scheduled for March 16-18, 2025. At this prestigious conference located in Dana Point, CA, Pharming’s Chief Medical Officer Anurag Relan, along with Michael Levitan, VP of Investor Relations and Corporate Communications, will partake in a fireside chat. This interactive session will occur on March 17 at 01:30 PM PT / 21:30 CET, providing an opportunity for attendees to gain insights directly from Pharming’s leadership team.
What to Expect
Investors attending the conference can anticipate a detailed discussion regarding Pharming's strategic initiatives, particularly their innovative therapies aimed at addressing rare and life-threatening diseases. This segment is crucial for understanding how Pharming continues to evolve within the biopharmaceutical market while catering to patients’ unmet medical needs.
About Pharming Group N.V.
Pharming Group N.V. stands at the forefront of the biopharmaceutical industry, committed to transforming the lives of patients grappling with rare and debilitating diseases. They are focused on commercializing a cutting-edge portfolio that features protein replacement therapies and precision medicines, which encompass both small molecules and biologics. Pharming's headquarters in Leiden, Netherlands, serves as the operational hub for a dedicated team that supports patients across over 30 markets spanning North America, Europe, Africa, the Middle East, and the Asia-Pacific region.
Innovative Solutions
The company's commitment to innovation is paramount, and as they work toward developing new treatments, they strive to enhance the quality of life for patients worldwide. Their ongoing research and development efforts are pivotal in driving forward the capabilities of biopharmaceuticals to address rare health conditions.
Connecting with Investors
For those interested in further information regarding the conference or wishing to set up one-on-one meetings with Pharming’s management, the Investor Relations team encourages reaching out directly. Those interested can contact Pharming through their Investor Relations email or connect with Roth representatives for additional details.
Contact Information
Individuals seeking to learn more about Pharming’s initiatives or the investor conference can connect through the following means:
Pharming Group, Leiden, the Netherlands
Michael Levitan, VP Investor Relations & Corporate Communications
Phone: +1 (908) 705 1696
Email: investor@pharming.com
Frequently Asked Questions
What is Pharming Group's main focus?
Pharming Group is dedicated to developing innovative therapies for patients with rare and life-threatening diseases.
Where will Pharming Group be participating in March?
Pharming Group will be present at the 37th Annual Roth Conference in Dana Point, CA, on March 16-18, 2025.
Who from Pharming will be attending the conference?
Anurag Relan, Chief Medical Officer, and Michael Levitan, VP of Investor Relations, will represent the company.
How can investors engage with Pharming Group?
Investors can contact Pharming’s Investor Relations team to schedule one-on-one meetings during the conference.
Where can I find more information about Pharming Group?
Additionally, more information can be found on their official website and other digital platforms.
